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Abstract 
This thesis aimed to study inflammation and adipogenesis capacity in human subcutaneous 
white adipose tissue with respect to the development of obesity and associated 
comorbidities, including insulin resistance.  
 Study I showed that the transcription factor, MAFB, was associated with increased 
adiposity and involved in regulation of TNFα-mediated inflammatory response, yet did not 
seem to directly influence adipogenesis or metabolism in human adipocytes. MAFB 
expression was upregulated during adipogenesis, and knocking down MAFB mRNA led to 
reduced TNFα-mediated inflammation. However, MAFB was highly expressed in white 
adipose tissue (WAT) macrophages, which most likely explains its association with BMI and 
metabolic syndrome.  
 Study II identified increased fat cell size as a hallmark of non-obese type 2 diabetic 
individuals. This hypertrophic status was associated with insulin resistance, inflammation 
and adipose tissue lipolysis indicating fat cell size to be a marker of pathogenesis. Relative 
amount of pro-inflammatory macrophages (M1/M2 ratio) correlated positively with fat cell 
size, lipolysis and TNFα secretion. In addition, early and late adipogenesis markers 
correlated negatively with fat cell size, suggesting impaired production of new fat cells in 
WAT hypertrophy.  
 Study III revealed that human adipocyte progenitors from subcutaneous WAT of healthy 
individuals consist of a single homogenous cell population. Furthermore, multiple 
macrophage subtypes were identified. We could not exclude that adipose progenitor 
subtypes might exist. However, any subtypes were not detectable by the methods employed 
in this study. Both findings are significant and warrant further investigation.  
 To conclude the finding in this thesis, we defined a role for MAFB in adipose tissue 
inflammation, which can possibly serve as a biomarker of insulin resistance and 
inflammation in WAT. Fat cell size seemed to be the best predictor for insulin resistance in 
non-obese individuals and this appeared likely connected to impaired adipogenic capacity of 
WAT. However, a search for different progenitor populations bearing varied abilities to 
become fat cells through the use of a single-cell RNA sequencing technique was not 
successful as only one major population of progenitors in healthy WAT was found. This 
demonstrated a need for further studies in larger cohorts of individuals characterized by 
different metabolic statuses.   
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Chapter 1         
Introduction 
1.1 Obesity 
Obesity is a preventable and non-communicable disorder defined by excessive body fat 
accumulation which impairs health. Body mass index (BMI) is a tool used to index body 
weight in relation to height in order to classify individuals as being underweight, 
overweight and obese. According to the World Health Organization, normal weight is 
defined as a BMI<25 kg/m2, overweight as BMI between ≥25 and <30 kg/m2 and obesity 
as BMI ≥30 kg/m2 [1-4]. In recent history, rates of overweight and obese individuals have 
grown so rapidly that obesity is considered an epidemic. In 2016, the World Health 
Organization estimated that 1.9 billion adults in the world were overweight and 
approximately 650 million adults were obese whereas in 2008 those numbers were 1.5 
billion and 500 million, respectively. Obesity is linked to the development of insulin 
resistance and type 2 diabetes, the prevalence of which has increased considerably [5].  
Further, obesity is associated with increased risk for fatty liver disease, hypertension, 
cardiovascular disease as well as cancer and neurodegenerative disorders like dementia 
[5-8]. Due to the vast number of obesity-linked pathologies there is considerable need for 
advancement in the understanding of mechanisms linking obesity and linked 
complications.  
1.2 Overview of white adipose tissue 
White adipose tissue (WAT) is a loose connective tissue, which is comprised of many 
cell types. The predominant population consists of large, lipid storing cells, referred to as 
adipocytes, which are functionally and morphologically distinct from cells found within 
the stroma vascular fraction (SVF) of adipose tissue. The SVF contains many cell types 
including adipocyte progenitor cells (preadipocytes), varied immune cells, fibroblasts and 
endothelial cells [9-11]. WAT can be found in many regions of the body but in humans it 
is commonly subdivided into subcutaneous WAT (scWAT) and visceral depots. The 
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relative importance in metabolism and inflammation between these depots has been a 
major research focus whereby this thesis primarily focused on scWAT.  
 Historically, WAT has primarily been implicated in thermal insulation, mechanical 
protection and energy storage. Thus, under conditions of excess caloric intake, non-
esterified fatty acids (NEFA) are taken up and stored in the form of triacylglycerol 
(TAG). Upon increased energy demand, TAGs are hydrolyzed into glycerol and NEFA, 
which are then released into the circulation. In target tissues, such as skeletal muscle and 
liver, NEFA are utilized as an energy source. The view on WAT was profoundly changed 
in the early 90’s when it was demonstrated that it secretes a number of peptides/proteins 
including leptin, tumor necrosis factor alpha (TNFα) and adiponectin, some of which act 
via endocrine mechanisms. The term adipokine was coined to describe the factors 
secreted from WAT in a time-dependent manner [12-15]. Over the years, >600 
adipokines have been described in different proteomic screens. The majority of the 
adipokines exert local effects on the tissue itself via paracrine signaling. Few adipokines 
exhibit endocrine function and are secreted into circulation where they impact other 
tissues, e.g. skeletal muscle, pancreas, liver and the central nervous system [16-20]. This 
draws focus on the potential of WAT to regulate whole-body metabolism as well as 
explain a role in for WAT expansion effects on other metabolically relevant tissues. 
1.3 Functions of the adipocyte 
An essential function of the adipocyte is to store TAG through a process termed 
lipogenesis and release energy in the form of glycerol and NEFA through lipolysis. The 
balance between these two enzymatic processes is primarily governed by insulin and 
catecholamines although other hormones may also play a role [21]. 
1.3.1 Adipocyte insulin response 
Islets of Langerhans are home to beta cells, which are the only known cell type to 
produce, process, and secrete the insulin hormone. In the most simplistic way, elevated 
blood glucose and incretin levels lead to a depolarization of the beta cells which 
ultimately lead to increased insulin release. Insulin binds to membrane-bound receptors 
and elicit signals in many cell types including hepatocytes, myocytes and adipocytes. 
Consequently, insulin has a prominent role in adipocyte biology where it regulates 
adipocyte development, metabolism, energy balance, and cell size [22, 23].  
 Insulin signaling upregulates the production and translocation of specific glucose 
transporters to the plasma membrane. In adipocytes, this primarily involves the glucose 
transporter GLUT4. Glucose is converted to dihydroxyacetone phosphate via glycolysis. 
Thereafter, dihydroxyacetone phosphate is converted to glycerol 3-phosphate by the 
enzyme glycerol phosphate dehydrogenase [24, 25]. Free glycerol can also be 
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phosphorylated to glycerol 3-phosphate by glycerol kinase. However, as this enzyme is 
expressed at extremely low levels in adipocytes, glycerol 3-phosphate is primarily 
produced via glycolysis. TAGs are subsequently synthesized via lipogenesis where three 
NEFA are sequentially coupled to one molecule of glycerol 3-phosphate. In order to 
enable this process, the NEFA need to be activated by the addition of a coenzyme A 
(CoA) molecule, which is catalyzed by the enzyme fatty acyl–CoA synthetase. Via the 
glycolytic pathway, glucose can also be used for the synthesis of NEFA in a process 
termed de novo lipogenesis. 
1.3.2 Adipocyte lipolysis 
Mobilization of fatty acids in adipocytes is carried out by a process termed lipolysis.  
Stored TAG are hydrolyzed where three NEFA are released from the glycerol backbone 
in a stepwise reaction. The first step is catalyzed by the enzyme adipose triglyceride 
lipase (ATGL), which can only hydrolize TAG to generate one NEFA molecule and a 
diacylglycerol and requires the co-activator protein CGI-58 for full hydrolase activity [26, 
27]. In the second step, the diacylglycerol is hydrolyzed by hormone-sensitive lipase, 
which generates a second NEFA molecule and a monoacylglycerol (MG) molecule [28-
30]. Although hormone-sensitive lipase exhibits both diacylglycerol and TAG hydrolase 
activity, it displays a highly selective preference to diacylglycerols [31, 32]. In the final 
step the MG is hydrolyzed by monoacylglycerol lipase [27]. NEFA is released into the 
blood where they bind albumin for transport to target tissues. Glycerol derived from 
lipolysis cannot be used locally by the adipocyte itself. Instead it is transported to the liver 
where it can be phosphorylated by glycerol kinase. Glycerol 3-phosphate can then be 
used for TAG synthesis, glycolysis or gluconeogenesis in the liver. Furthermore, lipolysis 
is stimulated by catecholamines and inhibited by insulin. Adrenergic signaling further 
regulates lipolysis through interaction with catecholamines, where epinephrine and 
norepinephrine are of most physiological relevance. In adipocytes, Perilipin 1 (PLIN1) 
coats lipid droplets where TAGs are stored and binds CGI-58 during an unstimulated 
state which physically occludes enzymatic activity of ATGL. Once catecholamines 
stimulate lipolysis, protein kinase A phosphorylates PLIN1 inducing a conformational 
change which thereby releases CGI-58 to activate ATGL [33].  In addition, protein kinase 
A phosphorylates HSL, which is activated and recruited to lipid droplet surface (27). 
1.3.3 Adipocytes in endocrine signaling  
Adipocytes and WAT have been shown to secrete a large number of peptide hormones. It 
is therefore important to consider the possibility of endocrine signaling between 
adipocytes and other constituent cell types. Adipocytes secrete adiponectin and leptin into 
the blood, which mediate appetite satiety as well as metabolic and inflammatory 
functions [20, 34, 35]. Several studies have indicated that adiponectin may potentiate an 
anti-inflammatory program in obesity and its comorbidities as it has been shown to exert 
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a positive impact on metabolism, blood pressure, as well as ectopic fat accumulation 
along internal organs [36-39]. Further, adiponectin has been shown to prevent 
macrophage foam cell formation [40]. Leptin signals satiety after meals and improves 
insulin sensitivity in target tissues [34]. It was initially thought to be a potential anti-
obesity treatment but subsequent studies showed that leptin is higher in obese subjects, 
which would be suggestive of a phenotype indicative of leptin resistance [41, 42]. 
1.4 Adipose tissue morphology and metabolic phenotype 
In addition to adipose tissue cytokines, the morphology of the adipose tissue has 
significant effects on the function of the tissue. With increasing adiposity, it becomes 
necessary to reorganize the tissue structure to enable adipose expansion. Adipose tissue 
can expand by either an increase in adipocyte volume or by an increase in adipocyte 
number.  
 
 
Figure 1.1 Adipose tissue hypertrophy leads to increased inflammation and insulin 
resistance [43]. Image used with permission from the publisher. 
Adipocyte size has been found to correlate with serum insulin and BMI [44-46]. 
Adipocyte hypertrophy—increased adipocyte size—has been correlated with plasma 
insulin concentrations and insulin resistance [21, 47, 48]. Moreover, a hypertrophic 
adipose tissue (Figure 1.1), characterized by fewer but larger adipocytes, is associated 
with a less favorable metabolic profile consisting of hyperinsulinemia and elevated 
inflammation in comparison to hyperplastic adipose tissue, which is characterized by 
more yet smaller fat cells [49]. Morphology differences seems to be of critical relevance 
in the  regulation and function of healthy adipose tissue.  
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1.5 Stroma vascular fraction 
While adipocytes comprise a majority of the WAT mass, they only constitute 20-40% of 
the total number of cells in the tissue [35, 43]. The SVF is a component of adipose tissue 
which encompasses the variety of non-adipocyte cells found within the stroma, or 
structural component of the tissue. The vast majority of these cells are adipocyte 
progenitors followed by immune cells, which include macrophages, CD8+ and CD4+ T-
cells, dendritic cells, B cells, neutrophils and mast cells [9, 50-52]. Studies have 
suggested that obesity is characterized by an increased number of immune cells in the 
SVF (primarily macrophages) resulting in a pronounced local enrichment of pro-
inflammatory cytokines [52]. The resulting chronic low-grade inflammation promotes the 
development of insulin resistance and contributes to type 2 diabetes [35, 53-58]. 
1.5.1 Adipose progenitor cells 
Without adipocyte progenitor cells, there would be no adipocytes. These are human adult 
stem cells, which are multipotent and thereby retain the ability to differentiate into a 
number of lineage fates including osteocytes, myocytes and adipocytes [59]. With the 
adipocyte turnover rate at approximately 10% per year [60, 61], WAT mass expansion 
can be mediated via increased adipocyte number (hyperplasia) and/or size (hypertrophy) 
[62]. As hypertrophy is closely linked to metabolic complications while hyperplasia is 
protective, much focus has been given to understanding how adipogenesis is regulated 
[63, 64]. Much progress has been made in cell and animal models and the major 
transcription factors and co-regulators have been identified. However, we still lack 
fundamental knowledge about the mechanisms in vivo in man and how these can be 
modified in a clinical setting.  
 
Figure 1.2 Wnt-signaling regulation of adipogenesis. Adapted from Gustafson et. al [67]. 
Dysregulated adipocyte size has become a focal point of clinical investigation where at 
present much knowledge is lacking. Adipose hypertrophy is associated with increased 
risk for type 2 diabetes independent of BMI where non-obese individuals with heredity 
for diabetes feature increased adipocyte size and insulin resistance, also reported in  
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Study II [21, 65, 66]. Factors affecting adipocyte size are poorly understood but are often 
believed to impair adipogenesis whereby Wnt-signaling has been implicated as a 
regulator of adipocyte differentiation (Figure 1.2) [49, 67-70]. Deciphering what 
underlying genetic mechanisms perturb adipogenesis and adipocyte metabolism has 
become a hot topic in adipose research where it is proposed that adipose progenitors are a 
heterogeneous population [71, 72] which formed the basis for Study III. 
1.5.2 Adipose tissue macrophages 
Adipose tissue macrophages (ATM) are important regulators of adipose tissue 
inflammation. In the lean adipose tissue ATM are likely to be involved in normal adipose 
tissue function and turnover by clearing the tissue from apoptotic cells, excess lipid and 
cellular debris [73, 74]. This population of ATM is referred to as M2-, or alternatively-
activated, macrophages, and primarily secretes anti-inflammatory cytokines, e.g. IL10 
[75]. In the obese state, it has been thought that monocytes are recruited from the 
circulation and accumulate in the expanding adipose tissue where they undergo 
polarization into a class of macrophages with pro-inflammatory phenotype known as M1-
macrophages, or classically activated macrophages [75]. M1 ATM release high levels of 
pro-inflammatory cytokines including TNFα, IL6 and monocyte chemoattractant protein 
1 (MCP1) which attract more monocytes from the circulation [57, 58, 76]. Additionally, 
M1-macrophages also stimulate lipolysis and inhibit insulin signaling in the adipocytes. It 
is not known what induces the polarization of macrophages in vivo but the processes 
probably involve release of several factors from the adipose tissue itself including 
exposure to palmitate, an inflammatory fatty acid [54, 77]. Whether adult macrophages 
are terminally differentiated is a matter of debate. Some studies showed that migration of 
bone marrow-derived monocytes into tissue was solely related to MCP1 and its receptor, 
CCR2 [53, 78, 79]. Other studies show that tissue resident macrophages harbor 
proliferative capacity [80-82] and are derived from the embryonic yolk sac [83-85]. 
Nevertheless, ATM number increases in obesity and contributes to the inflammation of 
the adipose tissue [52, 76].  
 It is important to understand the M1-M2 classification system of macrophages is more 
often considered to be an oversimplification of a very complex polarization spectrum in 
which the extremes, M1- and M2- macrophages, are studied. This classification system 
was the product of in vitro stimulated monocytes whereas macrophage phenotypes are 
variable among various tissues. In adipose tissue, macrophages subtypes have been 
described with mixed M1-M2 gene profiles [54]. These studies were primarily based on 
phenotype or cell surface markers that associate with the respective pro-inflammatory or 
anti-inflammatory phenotypes [86]. Further, the use of specific M1- and M2- macrophage 
surface markers is not completely consistent between studies. Recently, it has been 
suggested that there is another pro-inflammatory macrophage phenotype observed only in 
obese adipose tissue which undergo metabolic activation [77]. Kratz et al suggested that 
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macrophages might be polarized to a pro-inflammatory state due to a constant presence of 
high extracellular levels of lipid, glucose and insulin where markers of classical 
macrophage activation are absent and markers of fatty-acid and cholesterol metabolism 
are present [77, 87, 88]. 
1.6 Adipose tissue inflammation 
As mentioned above, obesity is associated with a chronic, low-grade inflammation of the 
adipose tissue and a dysregulation of the tissue function [35, 89]. However, inflammation 
is not just detrimental as it has been shown to also be advantageous for adipose tissue 
expansion and remodeling [90]. It is generally considered that altered function of the 
adipose tissue leads to changes in the storage of NEFA promoting lipid deposition in 
peripheral organs (lipotoxicity) which in turn increase the risk of developing insulin 
resistance and non-alcoholic fatty liver disease [89, 91, 92]. Several pro-inflammatory 
cytokines, such TNFα, IL6 as well as the MCP1 have been shown to affect WAT 
phenotype [76]. These factors affect gene transcription via transcription factors and 
kinases such as NFκB, MAPK etc. [93]. Several additional transcription factors 
regulating inflammatory responses have been described in recent years. Among these, V-
maf musculoaponeurotic fibrosarcoma oncogene homolog B (MAFB) is expressed in 
many tissues in both mice and humans [94, 95].  
1.6.1 Tumor necrosis factor alpha 
TNFα is an extensively investigated pleiotropic cytokine that affects cellular and 
biological processes such as immune function, apoptosis, proliferation, differentiation and 
metabolism [96-98]. The protein is synthesized as a 26 kDa transmembrane protein and 
reduces to 17 kDa soluble molecule after proteolytic cleavage. The processed TNFα 
monomers form trimers that bind to ubiquitously expressed transmembrane TNFα 
receptor 1 and 2. TNFα is a potent cytokine and a strong stimulator of inflammation 
pathways, (Figure 1.3) [96]. These signals are primarily attributed to an increase in NFκB 
activation and increased transcription of pro-inflammatory genes. The role of TNFα with 
respect to obesity and diabetes was first recognized and defined by Hotamisligil and 
Spiegelman in 1993 where they showed that adipose tissue mRNA expression of TNFα is 
induced in rodent models of obesity and diabetes [13]. Increased expression and secretion 
of TNFα from adipose tissue in obesity had thereafter been confirmed in human [99]. 
Knockout of the gene encoding TNFα has been shown to restore a degree of insulin 
sensitivity [100]. Furthermore, the primary source of TNFα within adipose tissue derives 
from cells in the SVF, namely macrophages [101]. 
 TNFα has been shown to affect adipocyte function and metabolism where it reduces 
the expression of genes involved in insulin signaling (insulin receptor (IR), GLUT4, and 
IRS1) or reduction in the adipogenesis master regulator, PPARγ [12]. PPARγ is central in 
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the regulation of genes with critical importance in adipocyte development and function. 
In addition, TNFα has been shown to activate kinases that promotes phosphorylation of 
serine residues on the IR and IRS1 which in turn diminishes insulin-induced tyrosine 
phosphorylation of IR and IRS1 and ultimately suppresses insulin signaling [12]. 
  
Figure 1.3 TNFα signaling pathway. Inhibitors used in Study I target p44/42 MAPK, JNK, 
and NFκB signaling.   
1.6.2 Monoctye chemoattractant protein 1 
Both mouse models with diet-induced or genetically-induced obesity (ob/ob) as well as 
obese humans display increased adipose mRNA expression levels of MCP1 (encoded by 
the CCL2) [78, 102-105]. As the name implies, MCP1 is a potent signaling molecule, 
which promotes migration of monocytes. High levels of MCP1 secretion have been 
linked to the enhanced infiltration of macrophages into the adipose tissue seen in obesity 
[104, 105]. Disruption of the CCL2 gene in mice placed on a high-fat diet leads to a 
reduced macrophage accumulation, insulin resistance and hepatic steatosis [78]. 
Moreover, stimulation of murine fat cells with MCP1 reduces insulin-stimulated glucose 
uptake into the cells [102]. These findings reveal MCP1 as an important link between 
obesity and obesity-associated metabolic disturbances. 
 MCP1 is secreted by cells in the stroma vascular fraction, e.g. ATM of adipose tissue 
as well as by adipocytes, although secretion from isolated adipocytes is significantly 
lower [78, 105]. Whether MCP1 from adipose tissue is released to the circulation has 
been a matter of debate and at least in humans, MCP1 primarily works as a local factor 
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[105]. Nevertheless, MCP1 seems to be an important factor for recruitment of monocytes 
from the circulation and therefore for the regulation of adipose inflammation.  
1.6.3 Musculoaponeurotic fibrosarcoma oncogene homolog B 
The transcription factor V-maf musculoaponeurotic fibrosarcoma oncogene homolog B 
(MAFB) is a basic leucine zipper transcriptional activator which belongs to the Maf 
family of transcriptional regulators. MAFB is expressed in many tissues in both mice and 
humans [94, 95]. MAFB has been shown to regulate fates of many cell types including 
macrophages, blood cells, beta cells and osteoclasts [106-111] Through its effects on 
macrophage differentiation, MAFB may have a role in inflammation. In a human 
monocyte cell line (THP1), it was demonstrated that TNFα stimulation not only induced 
MAFB expression but also promoted production of MCP1 [111]. MAFB has been 
implicated in insulin and glucagon control via transcriptional regulation has been 
previously implicated in metabolic processes such as insulin and glucagon transcription 
[112-116]. It was shown that CCAAT/enhancer binding protein δ (CEBPδ) controls 
transcription of MAFB in keratinocytes, which suggests that MAFB can be regulated by 
this transcription factor even in adipocytes [106]. Previously, the role of MAFB in the 
regulation of other metabolic processes in adipose tissue had not been well characterized.  
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Chapter 2          
Aims and Hypotheses  
2.1 General aim 
Finding new therapeutic targets in adipose tissue which impact obesity, insulin resistance 
and associated comorbidities is quintessential in the quest to slow the progression of these 
diseases. This thesis sought to broaden the current understanding of adipocyte and 
adipose tissue biology as well as adipose inflammation through the use of standardized 
clinical measures, molecular biology tools as well as the implementation of cutting-edge 
techniques. 
2.2 Specific aims 
I. MAFB is a highly expressed transcription factor that had yet to be characterized 
in WAT. The aim of Study I was to characterize MAFB in adipose tissue with 
respect to its impact on inflammation, obesity, insulin resistance and adipocyte 
biology. 
 
II. Obesity per se has a major impact on WAT pheotype. To elucidate the link 
between adipocyte size and inflammation in type 2 diabetes, and avoid the 
confounding effects of fat mass, Study II investigated WAT cell populations in 
non-obese men with type 2 diabetes and healthy age- and weight-matched 
controls. 
 
III. Study II found that increased adipocyte size is a major phenotype of WAT in 
non-obese T2D. This suggests that disturbed adipogenesis in precursor cells is an 
important mechanisms linking WAT to type 2 diabetes. Study III aimed to map 
adipose progenitor populations in human WAT by single cell RNA sequencing 
of SVF. 
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Chapter 3               
Comments on Methodology 
3.1 Cell cultures (In vitro and ex vivo cell systems) 
3.1.1 Tissue digestion & stromal vascular fraction isolation 
The separation of adipose tissue cell types, adipocytes and SVF, by enzymatic digestion 
was first described in 1964 by Rodbell [117]. This method utilizes collagenase which 
breaks the peptide bonds in collagen, a key component of the extracellular matrix. 
Collagenase II separation of adipocytes and SVF is preferential as it maintains the 
integrity of insulin receptors [118]. Once total cells are liberated from the tissue, 
adipocytes separate from the SVF by flotation due density differences owing to their high 
lipid content. In Study I, SVF was subjected to in vitro culture directly upon isolation or 
cryopreserved in FCS supplemented with 10% DMSO. SVF was solely cryopreserved in 
Studies II and III until the time of experimentation. 
3.1.2 Cell cultures 
Primary Progenitor Adipocytes 
Study I utilized primary adipocyte progenitors for in vitro experiments. Total SVF was 
directly cultured in adipogenic media. Adipogenic cells have adhered to the culture dish 
within 4-6 hours, and, during the course of in vitro stimulation, adherent cells without 
adipogenic capacity, including immune cells, have perished and have been washed away 
with media changes. The remaining cells are progenitor adipocytes which have begun the 
adipogenic differentiation program. PPARγ improves insulin sensitivity and is the 
principle driver of adipogenesis. In order to stimulate the adipogenic program, 
Rosiglitazone, a synthetic ligand of PPARγ, and insulin were included into the adipogenic 
culture media. Working with primary adipocytes is advantageous as it would reveal most 
closely what the in vivo response to given treatments would be. However, due to the 
fragility of mature adipocytes in vitro they are not suitable for all measures. Therefore, 
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SVF derived adipocytes have become a highly utilized and informative alternative which 
retains a degree of biological variability as compared to cell lines. 
Human Multipotent Adipose-Derived Stem Cells 
Study I utilized a cell line-like primary cell model system for studying adipose 
progenitors called human multipotent adipose-derived stem cells (hMADS). These cells 
were developed from primary SVF derived progenitor adipocytes, and expanded in vitro. 
These cells can be differentiated to fully functional adipocytes with respect to lipolytic 
response, insulin response and cytokine secretion as well as other lineages including 
myocytes, osteocytes and chondrocytes [119-122]. For expansion, FCS is added to the 
culture to induce proliferation while the addition of FGF2 maintains adipocyte 
differentiation capacity. The adipogenic program is stimulated as with primary 
progenitors by inclusion of Rosiglitazone and insulin into the culture medium. Cultures of 
hMADSs are relatively easy to work with in comparison to primary adipocyte progenitors 
and primary mature adipocytes. They are easily cryopreserved and expanded upon 
thawing. These cells serve well with very complex experimental designs where millions 
upon millions of cells may be necessary, and when a reduced degree of biological 
variation is desired. 
3.1.3 Human monocytic cell line 
The THP1 cell line was used in Study I. This immortalized monocyte cell line is derived 
from the peripheral blood of a 1-year old human male with acute monocytic leukemia. 
These cells exhibit a large and round morphology with a low degree of aggregation in 
suspension. Through stimulation with phorbol 12-myristate 13-acetate, these cells can be 
differentiated from monocytes into M0, or non-activated macrophages [123, 124]. These 
cells are highly plastic and can yield M1 or M2 macrophage subtypes with appropriate 
stimuli [124]. These subtypes were not assessed in this thesis as it was beyond the scope 
of each study; THP1 cells were investigated solely in an undifferentiated state. THP1 
cells offer the advantages of ease of expansion and low biological variability. THP1 
monocytes are ideal for studies which aim to identify intracellular signals of a particular 
cytokine or factor, such as Study I. 
3.2 Lipolysis 
In Study I, we studied the effects of MAFB knockdown on adipocyte lipolysis. 
Adipocytes were incubated in culture with and without lipolytic agents for 3 hours. In our 
studies, the drug isoprenaline was utilized to induce lipolytic response. Isoprenaline is 
structurally similar to adrenaline, but it acts as an agonist for only β adrenergic receptors.  
Lipolysis was measured as free glycerol release into conditioned media by a fluorescence 
reader. This is a preferential to quantifying NEFA molecules as a measure of lipolytic rate 
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as adipocytes cannot recycle glycerol as they lack glycerol kinase and cannot convert free 
glycerol to glycerol 3-phosphate, which is essential for NEFA esterification to form TAG 
[125].   
3.3 Gene expression  
3.3.1 Quantitative real-time polymerase chain reaction 
Conventional polymerase chain reaction took a vast leap forward when thermal cyclers began 
to incorporate fluorescence detection. Polymerase chain reaction (PCR) transformed from 
simply amplifying a transcript of a target gene or sequence where the critical output was the 
quantity of the generated amplicon into a much finer tool. Fluorescence labeling and 
detection enabled the ability to measure DNA amplification during the log linear phase of 
PCR amplification and made it a quantifiable measure in real-time, known as real-time 
quantitative reverse transcription PCR.  
 qRT-PCR is used to quantify specific transcripts of interest. Briefly, total mRNA is 
extracted and purified from cells or tissue. It is then reverse transcribed to complementary 
DNA (cDNA) using random hexamer or oligo dT primers and reverse transcriptase. The 
cDNA is loaded into the qRT-PCR reaction where it undergoes thermal cycling and 
transcriptome amplification. Critical components of this measure include Taq DNA 
polymerase for amplification, a fluorescence label for transcript quantification, and a thermal 
cycler with fluorescence detection. Gene expression is calculated in relation to stably 
expressed reference genes, also known as a housekeeper genes, which do not vary in the 
conditions tested, and quantified by the delta-delta Ct method [126]. 
 Studies I and II utilized two widely used chemistries for the detection of transcripts of 
interest, SYBR Green and Taqman probes.  
 SYBR Green is a double stranded DNA (dsDNA) binding dye that intercalates 
nonspecifically into dsDNA polymers irrespective of sequence. When bound to dsDNA, the 
dye emits light. The essential requirement is that the polymer is dsDNA. Due the 
nondiscriminatory nature of this dye it detects specific products as well as nonspecific 
products including primer dimers; this can lead to false positives. This drawback can be 
overcome with well-designed primers which take into account sequence specificity as well as 
slight modifications to thermal cycling temperatures to limit unspecific binding. When 
oligonucleotide primers are designed with care and properly tested by use of melt curves and 
efficiency testing with cDNA standards, this method can yield highly specific and 
quantifiable data on gene expression. The cDNA input is relatively low, and the assay is very 
cost effective.  
 Taqman® assays utilize a very different fluorescence chemistry altogether. These 
assays are supplied with a specific probe for the target sequence as well as forward and 
reverse primers for the sequence of interest. The probe is a oligonucleotide which binds a 
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specific sequence between the primers. Further, the probe incorporates a reporter dye at 
the 5’ end and a quenching dye at the 3’ end. The quenching dye stifles the ability of the 
reporter dye to emit light when in close proximity to each other. Once the dsDNA is 
denatured, the temperature is lowered to enable probe and primers to anneal to their 
specific target sequences. During the next step of the PCR, the Taq DNA polymerase 
synthesizes new DNA strands from the unlabeled primers and the template cDNA. Once 
the polymerase reaches the probe, its 5’ nuclease activity cleaves the probe, which 
separates the reporter and quencher dyes enabling fluorescent light emission. Through 
repeated cycles, the emitted light is proportional to the amount of synthesized target 
sequence which in turn reflects the amount of starting material. Taman® assays are 
considered the gold standard for quantitative genomic analyses and are well-cited. 
However, these assays while specific are costly and require larger material input than 
SYBR Green. 
3.3.2 Microarray profiling 
Gene expression profiling across the entire genome by microarray provides the possibility 
to measure and compare the mRNA expression of a very large number of transcripts 
(>540 000) between different conditions or between specific cell types, as performed in 
Study III. Genome wide mRNA expression measurement and analysis had been a well-
established method in comparison with contemporary global mRNA transcript detection 
technologies, inclusive of RNA sequencing and Cap Analysis of Gene Expression. Clear 
benefits to utilizing microarray technologies are that they are much more cost effective 
and input of biological material is minimal. Additionally, there is an option to amplify the 
mRNA in order to further minimize biological sample input while maintaining robust 
data quality. Data sets produced are readily comparable between batches however 
detection limits are present given that the probe set included in the microarray may not 
bind all available transcripts or binding affinity can be slightly different for specific 
transcripts, which affects measures of expression level. Thereby, this is a limiting factor 
of the technology. Data analysis is easily computed with free software packages available 
in the computing software, R. Further limiting, this technology cannot measure absolute 
levels of mRNA expression due to varying binding affinities between gene transcripts and 
respective probes included in the array. Therefore, common practice is to validate key 
findings with this technology by real-time quantitative reverse transcription polymerase 
chain reaction, qRT-PCR. 
3.3.3 C1 single-cell auto prep integrated fluidic circuit 
Study III utilized the C1 single-cell auto prep system for RNA sequencing of individual 
cells in human SVF. This system operates by way of a microfluidics chip with 96 capture 
sites designed to retain individual cells with diameters between 10-17 micrometers. SVF 
cells were prepared in a single-cell suspension and loaded onto the chip. Doublet 
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discrimination was performed by microscopy and checked by an automated Matlab image 
analysis algorithm. Lysis, reverse transcription and PCR amplifications were performed 
using the C1 instrument script. The cDNA quality was assessed by an Agilent 
BioAnalyzer. Thereafter, cDNA was fragmented and barcoded. Sequencing was 
performed on an Illumina HiSeq 2000.  
 Benefits to using the C1 system include ease of operation and an automated workflow. 
However, there is an inherent bias in that one would need to select an IFC with a 
particular capture site designed for a specific range of cell diameters, which is a limiting 
factor. A similar study could have been performed with a less established protocol by 
way of single-cell flow cytometry based sorting. While the flow cytometry method is a 
less-well established method for single cell sorting, it offers the potential of high-
throughput indexing the cells that are sorted by tagging surface proteins. The C1 system 
has this capability if coupled with a fluorescence microscope but at a greatly reduced 
throughput which would in turn affect cell viability prior to cell lysis. This would enable 
mRNA to be correlated to membrane protein expression. This, however, would introduce 
bias as a critical limitation at the time was a theoretical maximum of 18 fluorescence 
channels for sorting. Both options, however, would require the assistance of a 
bioinformatician, or extensive bioinformatics training, to evaluate the data output. 
3.4 Studying protein expression 
As mRNA levels do not always reflect corresponding protein expression levels, it is 
important to measure both when feasible. Protein may not always reflect mRNA levels as 
mRNA can be degraded before translations, protein can have a short half-life, as well as 
tight regulation of protein secretion [127, 128]. 
3.4.1 Western blot 
Western blot is a widely used technique for the detection of protein expression and was 
implemented in Study I. Proteins are loaded into wells of a polyacrylamide gel alongside 
a known protein molecular weight standard. Current is passed through the buffering 
solution containing sodium dodecyl sulfate (SDS) which causes proteins to undergo 
electrophoretic shift and maintain a denatured state. Factors which may affect the 
separation include isoelectric point, molecular weight, and the charge of the protein. 
When proteins are denatured they shift through the gel and separate by molecular weight 
where smaller proteins migrate more quickly than larger proteins. Proteins are then 
electrophoretically transferred to a positively charged membrane. The membrane 
undergoes blocking and probing with a primary antibody specific to the protein of 
interest. This is followed by incubation with a secondary antibody specific to the primary 
antibody to amplify the detection signal. The secondary antibody may be enzymatically 
labeled or fluorescently labeled whereby detection can be determined by 
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chemiluminescence or fluorescence detection, respectively. Western blot analysis yields 
visual evidence of protein expression. Though protein band density may be quantified, it 
is not a robust measure which can be readily compared between membranes. Additional 
considerations are that proteins often undergo post-translational modifications which 
affected the size and charge of the protein, and ultimately, the electrophoretic shift. This 
can reveal a bands at sizes other than the theoretical or reported molecular weight. 
Furthermore, proteins may not denature completely and may even degrade which would 
block or completely destroy the epitope where the antibody would bind. While 
informative, the outcome of this method is highly variable. 
3.4.2 Enzyme-linked immunosorbent assay 
Studies I and II utilized Enzyme-linked immunosorbent assays (ELISA) for protein 
detection. ELISAs are reliable alternatives to the western blot for protein detection. 
ELISAs are highly quantifiable and can be performed in a fraction of the time it takes to 
perform a traditional western blot. Protein standard and lysates are loaded onto a 
microplate pre-coated with antibodies specific to the target protein. Thereafter, the protein 
is probed with a detection antibody and a secondary antibody which is specific to the 
detection antibody. The secondary antibody contains an enzyme, often horseradish 
peroxidase, which will catalyze the substrate solution and change its color. The color 
change can then be measure with a spectrophotometer, and concentration determined by 
comparison to the protein standard. ELISA requires much less material than a western 
blot. Furthermore, conditioned medium from cell or tissue culture can be used to 
determine levels of protein secretion. A concern is antibody specificity, affinity and 
cross-reactivity. If the detection antibody is promiscuous then quantification is unreliable.  
Thus, whenever possible ELISA and Western blot should be used in complement. 
3.5 Fluorescence-activated cell sorting 
Flow cytometry is a laser based technology which enables the detection of physical and 
chemical properties of cells which pass through a finely focused fluidic stream at a very 
high rate. In its purest form, cytometry is used for studying cell characteristics including 
counting cells, cell size, protein expression, and much more. In principle, as the cells pass 
through the laser line, they refract light and these light scatter properties are detected.  
Cells of a specific cell type have very similar light scatter properties, or signatures. In 
fluorescence based flow cytometry, cells are marked with antibodies with high affinity 
for specific proteins. The light scatter signatures of each marker incorporated in the 
staining cocktail and degree of expression by cells in the sample are used for analysis to 
identify cells with marker expression similarities to define specific cell populations.  
 This technique enables researchers to obtain highly specific information from many 
individual cells. Study III utilized fluorescence-activated cell sorting (FACS) to 
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characterize many cell types within adipose tissue and sort specific populations of cells 
for further investigation. Comparable techniques include fluorescence microscopy and 
time of flight mass spectrometry (CyTOF). CyTOF was not pursued in this study as it 
requires access to bioinformaticians for data quality assessment and down-stream 
analyses. Fluorescence microscopy offers such benefits as being a directly visual 
assessment, inexpensive by comparison, ease of sample preparation and simplicity of 
analysis. It falls short of sensitivity when compared to flow cytometry with respect to the 
number of detection parameters. Flow cytometry has the advantage of yielding large 
amounts of data which can be relatively easily assessed in a short amount of time. 
Limitations include spectral overlap between fluorochromes, cellular autofluorescence 
and the number of parameters which can be evaluated in a given panel. It is of critical 
importance for the reliability of this technique that specific biological and technical 
controls be incorporated into the design. These considerations were made during the 
design of Study II and Study III. 
3.5.1 Marker selection 
Marker selection is a critical step in the design of any flow cytometry based experiment. 
Ideally, the cell population of interest will express a specific cell surface protein which 
can be used as a marker of that population while other cell types in the same sample will 
not express this marker. This is easily adjusted for when performing flow cytometry 
experiments on in vitro stimulated cell lines as these typically encompass one individual 
cell type where the marker variation is negligible and the output of interest is variation of 
few parameters. This becomes much more complicated when using heterogeneous 
samples, such as SVF in Study II and III which encompasses many different cell types 
including immune cells, adipocyte progenitor cells, endothelial cells, and many more. 
Antibody isotype controls are less necessary these days with the reliability of antibody 
production from reputable sources but can still be useful when detecting lowly expressed 
markers and when working with cells which highly express Fc receptors to determine the 
signal associated with nonspecific antibody binding. 
 These considerations were made during the design of Study II and Study III where 
adipose progenitors (CD45-/CD31-/CD34+), CD4+ T cells (CD45+/CD3+/CD19-
/CD4+/CD8-), CD8+ T cells (CD45+/CD3+/CD19-/CD8+/CD4-) M1-ATM (CD45+/ 
CD14+/CD11+/CD206+), and M2-ATM (CD45+/CD14+/CD11-/CD206+) as well as 
total T cells (CD45+/CD3+/CD19-) and total ATMs (CD45+/CD14+/CD206+) were 
sorted for further analysis. 
3.5.2 Panel design 
Each antibody is conjugated to a fluorochrome, a chemical dye which emits light upon 
excitation by specific light wavelengths. When pairing antibodies and fluorochromes for 
improved resolution, it is important to consider the expression of the marker on the cells 
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to be interrogated in addition to the emitted light brightness of the fluorophore, e.g. lowly 
expressed markers paired with bright fluorophores and vice versa. Typically, 
fluorophores will be maximally excited by one laser which will result in light emission of 
a varying range of wavelengths. The detection apparatus will narrow the range to specific 
wavelength interval which reduces the capacity for spectral overlap. An ideal 
fluorochrome will incorporate a fluorophore with a long emission wavelength, large 
Stokes shift, high extinction coefficient, and high quantum efficiency. Even when 
adjusting for these considerations, spectral overlap will occur, Figure 3.1. Thus, 
compensation calculation software is necessary which performs a mathematical 
correction to adjust the cytometric data for the contributions of a given fluorochrome to 
all other fluorescence channels [129]. Single stain controls on protein coated 
microparticles are necessary for setting up channel detection measures for compensation 
calculation; with highly expressed proteins where microparticles are insufficient it 
becomes necessary to stain individual markers on cells. To control for fluorescence 
spillover and reduce false positives associated with spectral overlap, fluorescence minus 
one (FMO) controls are considered the gold standard; these include all fluorochromes 
except for one to identify the contribution to the signal of all colors in the panel except for 
the one designed for the given channel. Ideally, FMOs should always be included for all 
channels in complex panels. 
 
Figure 3.1 Spectrum viewer visualization of the spectral overlap between four 
fluorochromes used in Study II excited using the 561 nm laser. Created using BD 
Biosciences Spectrum Viewer tool. 
3.6 Clinical metabolic measures 
3.6.1 HOMA 
The homeostatic model assessment -Insulin Resistance (HOMA-IR) method is a model 
used to quantify insulin resistance based on a mathematical formula developed by 
Matthews in 1985 [130]. It is calculated by: 
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HOMA-IR   =   fasting blood glucose ·  fasting plasma insulin 
22.5
 
 
As it is based on fasting hormone levels HOMA-IR primarily reflects hepatic insulin 
resistance. A normal HOMA-IR value is 1 but there is no unanimously accepted cut-off 
to define insulin resistance. Values up in the range of 1.7-2.0 may be therefore be 
considered normal, while values above 2.3-2.5 are often defined as insulin resistance 
[131, 132]. The HOMA model is easy to use as it requires a single fasting plasma sample 
assayed for insulin and glucose levels. While there are other methods to indirectly 
estimate insulin sensitivity by fasting plasma measures (e.g. QUICKI, Matsuda etc), 
HOMA-IR is still widely used and it has proven to be a robust clinical measure in the 
assessment of diabetes pathophysiology in larger cohorts. 
3.6.2 Hyperinsulinemic euglycemic clamps 
The patients in Study II underwent a hyperinsulinaemic–euglycaemic clamp procedure 
as described by Hagstrom-Toft et al. [133]. In brief, a bolus dose of insulin was delivered 
intravenously (1.6 U/m2 body surface area) and then an insulin infusion was delivered 
intravenously (0.12 U/m2 min) for 120 min. Every fifth minute, blood glucose values 
were measured in duplicate and euglycaemia was maintained by a variable intravenous 
infusion of glucose (50 mg/ml). The measurements from the last 60 min of the clamp 
were used for calculations of glucose-disposal rate, M-value. During this phase, the 
insulin levels remained steady (mean ± SD 1,669 ± 528 pmol/l). The hyperisulinaemic-
euglycemic clamp is considered the gold standard for insulin sensitivity assessment. 
When using high insulin infusion levels (0.12 U/m2 min), the M-value primarily reflects 
insulin sensitivity in skeletal muscle as glucose uptake in the liver is virtually abrogated. 
To measure hepatic glucose uptake requires lower insulin concentrations and isotope-
based tracer techniques. Clamps are labor intensive, time consuming and expensive 
procedures which are further impacted by patient availability. It is therefore primarily 
used when the study size is small. 
3.7 Ethical approval 
These studies were performed in accordance with guidelines set forth by The Declaration 
of Helsinki and approved by regional ethical committees. All participants received 
detailed information on the studies. Oral and written informed consent was obtained. 
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Chapter 4         
Results 
4.1 Study I: MAFB 
In Study I we demonstrate that MAFB mRNA expression increases with increased BMI, 
is enriched in ATM, and that MAFB mediates TNFα effects in adipocytes and THP1 cells 
used as macrophage model.  
 Using Cohort 1, we compared non-obese and obese individuals where MAFB 
expression correlated positively with BMI, (Study I, Figure 1). This finding was 
confirmed in a second cohort where MAFB was also strongly correlated with metabolic 
syndrome. Multiple regression analysis in this cohort revealed that approximately 60% of 
the variation in MAFB expression is attributed to both BMI and the metabolic syndrome 
(Study I, table 1).  Furthermore, MAFB regulation by adipose mass was established in a 
third cohort of patients undergoing weight reduction where MAFB expression in scWAT 
was diminished.  
 To investigate MAFB association with adipocyte metabolism, insulin-stimulated 
lipogenesis and isoprenaline-stimulated lipolysis measurements were performed on 
adipocytes from all subjects of cohort 1.  Here we observed negative correlations between 
scWAT MAFB expression and both stimulated lipogenesis and stimulated lipolysis of 
isolated adipocytes (Study I, Figure 2), which remained significant after adjusting for 
BMI. Further, MAFB held a correlation to adipocyte size which suggested a role for 
MAFB in impaired adipocyte biology and possibly hypertrophy, Figure 4.1 (unpublished 
data). 
 As MAFB has been reported to be involved in development and differentiation 
programs in other cell types, we next looked at the impact of MAFB on adipogenesis. We 
found that MAFB was strongly induced during adipogenesis, but knockdown of MAFB 
by siRNA had no effect on lipid accumulation, basal lipolysis, basal lipogenesis or 
stimulated lipogenesis in human adipocytes (Study I, Figure 3). However, the TNFα 
repression of lipid accumulation and upregulated lipolysis rate were abrogated when 
 24 
MAFB was knocked down indicating that MAFB expression is a requisite factor for 
TNFα mediated effects on human adipocytes. These results set the stage to investigate a 
role for MAFB in adipose tissue inflammation.  
 
Figure 4.1 MAFB mRNA expression in adipose tissue from cohort 1 correlates with 
adipocyte hypertrophy (r=0.47, p<0.001). 
The next step was to investigate MAFB regulated inflammation in adipocytes.  In vitro 
knockdown of MAFB mRNA alone did not affect expression of the inflammatory genes 
CCL2, IL6 or IL8. However, TNFα, as expected, drastically upregulated the expression of 
these genes in mature in vitro differentiated adipocytes. SiRNA targeting of MAFB 
yielded no effect on TNFα-induced upregulation of CCL2 or IL8, but the stimulation of 
IL6 expression was indeed repressed by approximately 50% (Study I, Figure 4). Similar 
effect was observed on IL6 protein secretion and thereby demonstrated MAFB 
involvement in regulation of inflammatory phenotype of adipocytes. 
 MAFB upregulation by TNFα has been reported in macrophages. Although we could 
confirm concentration-dependent MAFB upregulation by TNFα in THP1 cells, the effects 
in adipocytes were inversely regulated (Study I, Figure 5). In addition, TNFα mediated 
effects were present already at 6 hours of stimulation and further pronounced with 
prolonged stimulation up to 24 hours. To investigate which kinases in the TNFα signaling 
pathway were involved, adipocytes and THP1 monocytes were treated with kinase 
inhibitors specific to c-Jun N-terminal kinase (JNK), p44/42, and NFκB prior to 
stimulation with TNFα. TNFα downregulation of MAFB in adipocytes was only partially 
rescued by JNK inhibition whereas both JNK and p44/42 inhibitors significantly 
suppressed the TNFα induced upregulation of MAFB in monocytes (Study I, Figure 5), 
which is further evidence of differential regulation in the two cell types.  
 As MAFB is downregulated by pro-inflammatory cytokine TNFα in adipocytes, but 
upregulated in THP1 monocytes and obesity, we hypothesized that the observation in 
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obese patients could be due to macrophage infiltration or phenotypical change due to 
inflamed adipose environment. To assess this, scWAT macrophages and leukocytes were 
sorted from scWAT SVF and gene expression was compared with paired adipocytes from 
6 patients which revealed that macrophages are major cell type expressing MAFB (Study 
I, Figure 6). In addition, there was no difference in MAFB expression in adipocytes from 
lean and obese patients. Furthermore, MAFB expression strongly correlated with CD14 
(monocyte/macrophage marker) expression in WAT. 
4.2 Study II: Increased fat cell size 
In Study II, we observed that non-obese men with type 2 diabetes (n=14) had 
significantly larger fat cells than healthy subjects (n=13) matched for gender, age, BMI 
and total fat mass. Diabetic subjects differed from healthy subjects only in clinical 
measures expected of the diagnosis, e.g. Hba1c, plasma glucose, plasma insulin, HOMA-
IR, and M-value. Glycerol release and secretion of inflammatory proteins did not differ 
between the groups (Study II, Table 1). In the entire cohort fat cell size correlated 
positively with HOMA-IR, glycerol release, TNFα secretion. Further, TNFα secretion 
correlated with glycerol release and HOMA-IR (Study II, Figure 1). 
 Next we analyzed adipose stromal cells from this cohort by flow cytometry. Population 
frequencies were normalized to the total number of viable cells (Study II, Table 2) and 
did not differ between the groups. Although the average frequency of M1 ATM was 
twice as high and the ration of T cells to B cells was approximately 1.5 as high in diabetic 
patients compared to healthy controls, these values were not significantly different due to 
large inter-individual variation (visualized in Study II, Figure 2). This may also be 
reflective of the small sample size. While a larger cohort for this characterization would 
be ideal it is not feasible.   
 Given a seeming tendency of macrophages to be approximately doubled in diabetes 
subjects compared to healthy controls, we were interested if there was any macrophage 
association with fat cell size across the entire cohort. We observed a positive correlation 
between the M1/M2 ATM ratio and fat cell size. In addition, this ratio positively 
correlated with both TNFα secretion, and glycerol release (Study II, Figure 3).  
 Genes involved in cell commitment (BMP4, DKK1, and WISP2) and regulation of 
adipogenesis (CEBPA, PPARG, EBF1, and SLC2A4) were quantified in adipose 
progenitors or intact tissue, respectively. BMP4 in progenitor cells correlated negatively 
with fat cell size (Study II, Figure 4). DKK1 (negative) and WISP2 (positive 
adipogenesis regulators) exhibited near significant trends in relation to fat cell size. In 
adipose tissue, CEBPA, PPARG, EBF1 and SLC2A4 mRNA exhibited strong negative 
correlations with fat cell size (Study II, Figure 5). 
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4.3 Study III: Single-cell transcriptomics 
The transcriptomes of 574 individual cells from four healthy women were analyzed by 
clustering and visualized through t-distributed stochastic neighbor embedding (Study III, 
Figure 1a-b). Four distinct groups of cells were identified by a fist level clustering of SVF 
by cell and gene expression based on 2000 most variable genes. Each cluster was evident 
in all four individuals, and further evident by t-SNE projection. We identified the genes 
that best characterized each cluster and mapped them back to microarray data from FACS 
sorted SVF of scWAT (Study III, Figure 1c-d). We found that the largest fraction was 
indeed adipose progenitor cells while the 3 minor fractions were ATM of M1-like, M2-
like and an intermediate phenotype.  Key marker genes of each cell type were projected 
onto the t-SNE plot to confirm the predicted populations (Study III, Figure 1). 
Interestingly, only macrophages demonstrated sub-clusters, adipose progenitor 
transcriptomes did not.  
To further investigate the possibility that adipose progenitors include some additional 
subtypes, a second level clustering was performed in which most variable genes within 
progenitor cluster were identified and then cell and gene clustering was performed and 
visualized by heatmap (Study III, Figure 2a). However, no subtypes appeared evident. 
Additionally, the transcriptomes were assessed for rare cells but this too yielded no 
distinct subtypes. In light of no clear sub-clusters of adipose progenitor cells, we 
evaluated a hypothesis that cells might be discernable by stage of differentiation. To this 
end, we placed cells along a pseudotemporal ordering in t-SNE projection and screened 
for pseudotime-dependent genes (Study III, Figure 2b).  Seventy such genes over the 
significance cutoff point were found. Collagen genes, CD55 and Thy1 were among the 
most highly expressed genes in the beginning of pseudotime while ribosomal genes and 
KLF4 were elevated towards the end of the pseudotemporal space (Study III, Figure 2c). 
While we were able to separate adipose progenitor cells into four pseudotime-dependent 
states, amplitude differences in gene expression between the states were very minor. 
Furthermore we were unable to distinguish between the states when projected on t-SNE 
plot of the entire data set. Thus we found no evidence that adipose progenitors constitute 
a heterogeneous population in healthy human adipose tissue.   
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Chapter 5           
Discussion 
In Study I, we observed an increase in MAFB expression in obese adipose tissue. MAFB 
expression is enriched in macrophages whereby it is differentially regulated in 
macrophages and adipocytes. Further, we demonstrated that MAFB mediates TNFα-
induced inflammation in adipocytes. 
 MAFB has been shown to regulate differentiation programs in a variety of cell types 
[106-109]. Our study showed that MAFB did not directly influence the adipogenesis 
process in human adipocytes as it did not affect lipid accumulation when MAFB was 
knocked down before induction of differentiation. However, MAFB expression was 
strongly induced by adipocyte differentiation which implied the possibility of its role in 
metabolism in the mature adipocyte. Its upregulation during adipogenesis could be in part 
due to regulation by CEPBD, as similarly reported in keratinocytes [106]. As MAFB 
expression correlated with fat cell size, it is feasible that Wnt-signaling in conjunction 
with the early adipogenic transcriptional regulator CEPBD work in concert to mediate 
hypertrophy. 
 MAFB expression was differentially regulated by TNFα in adipocytes (suppressed) 
versus macrophages (induced), in addition it strongly correlated with CD14 (Study I, Fig 
6C) and CD68 (data not shown), markers of adipose tissue macrophages. Thus, we draw 
the conclusion that MAFB is a good marker of macrophage abundance in WAT. 
Therefore, the elevated MAFB mRNA levels which correlate with increased adiposity 
(BMI) are likely due to increased macrophage content in WAT. Alternatively, MAFB can 
also show the increased pro-inflammatory phenotype of adipose tissue as its expression in 
macrophages is induced by TNFα. So even though MAFB is expressed in adipocytes, it is 
likely that in intact WAT the contribution by macrophages outweighs adipocyte 
expression and MAFB mRNA correlations with clinical measures are likely driven by 
macrophages. 
 The major role of MAFB in adipocytes appears to be as a mediator of inflammation. 
MAFB seems to be required for TNFα signaling mediating upregulation of some 
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inflammatory genes (IL6) (Study I, Fig 4). Interestingly, MAFB is downregulated by 
TNF, but is required for TNF signaling, which could suggest some compensatory 
protective feedback loop to keep inflammation at low levels. One could speculate that 
further therapeutic downregulation of MAFB in adipocytes could be protective against 
obesity-induced WAT inflammation. However, the mechanism how MAFB interacts with 
protein components of TNFα signaling is unknown.   
 In Study II, we analyzed adipose tissue metabolism, morphology and stromal cells 
isolated from scWAT biopsies in a clinically characterized cohort of non-obese men with 
and without type 2 diabetes by fluorescence activated cell sorting followed by gene 
expression studies.  
 Although type 2 diabetic patients differed from healthy subjects in the expected clinical 
measures, there were no differences in lipolysis or inflammatory protein secretion 
between the two groups. Therefore, one could speculate that these measures are closer 
linked to obesity than type 2 diabetes. Adipocyte hypertrophy was the principal factor 
differentiating type 2 diabetes subjects from healthy individuals. This suggests that 
adipocyte hypertrophy is an important phenotype linking WAT to type 2 diabetes. In line 
with this, we found correlations between fat cell size and HOMA-IR, glycerol secretion, 
and TNFα secretion. We, therefore, identified fat cell size as a phenotype worth further 
investigation. Previous studies showed that macrophage abundance is elevated in 
unhealthy adipose tissue in subjects with or without the metabolic syndrome [52]. 
However, upon 13-color analysis and sorting by flow cytometry, we further could not 
separate the two groups as there were no significant differences in SVF cell population 
frequencies between the groups. This was a surprising finding given the elevated 
inflammation typically associated with insulin resistance and the metabolic syndrome in 
adipose tissue. However, we noticed that macrophage frequencies appeared to be doubled 
in type 2 diabetes subjects but the difference was not significant due to large inter-
individual variation and the small cohort size, even though the size is similar to 
comparable studies [134-136]. In addition, we observed correlations between fat cell size 
and the M1/M2 ATM ratio and this ratio also correlated with basal lipolysis as well as 
TNFα secretion. This evidence is in line with findings from Study I owing, at least in 
part, adverse metabolic and inflammatory phenotypes in adipose tissue to the presence of 
pro-inflammatory macrophages. 
 Which molecular mechanisms are at play in adipocyte hypertrophy? Previous studies 
by the Smith laboratory suggested defective adipogenesis linked to WNT-signaling [67-
70, 137, 138]. It has been shown that BMP4 plays a critical role early in the adipogenesis 
program by dissociating WISP2 (a Wnt-signaling molecule and negative regulator of 
adipogenesis) from the PPARγ transcriptional activator ZNF423 (a positive regulator of 
adipogenesis). This allows ZNF423 to relocate to the nucleus to initiate adipogenesis. Our 
observation of a negative correlation between adipocyte fate and adipogenesis regulating 
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genes and fat cell size in WAT are in line with diminished capacity of WAT to produce 
new fat cells in hypertrophy.   
 Taken together we find that non-obese diabetic subjects have larger fat cells than their 
healthy counterparts and most likely exhibit an impaired adipogenesis program. Adipose 
tissue hypertrophy rather than specifically diabetic status is an indicator of a reduced 
metabolic capacity and impaired insulin sensitivity in scWAT.  
 In Study III, we investigated the possible heterogeneity in adipocyte progenitor cells 
by single cell mRNA sequencing of total resident SVF in WAT as has been reported in 
murine and human studies [139-142]. Some studies show that scWAT derived progenitor 
cells are more enriched in adipogenic transcriptional regulators than progenitor cells in 
visceral adipose depots in human [143-146]. Further, scWAT progenitor cells express 
higher levels of adipogenic transcription factors during adipogenesis than visceral derived 
cells [145]. Given the findings in Study II in addition to the aforementioned previous 
reports, we hypothesized that adipocyte progenitor cells might have multiple activation 
states or subtypes which predispose hypertrophy, or hyperplasia, in WAT which could 
explain why these states differ between patients with varying adiposity and metabolic 
status. Contrary to our hypothesis, the principle finding is that, at least in healthy 
individuals, human adipocyte progenitor cells constitute a single, homogeneous 
population. 
 A pseudotemporal ordering of revealed a gradient expression of 70 genes deemed 
significant. Along the pseudotime, typical markers of adipogenic capacity (CD34, CD36, 
PDGFRA) were not present, where other known markers (CD55, SFRP4, SEMA3C) 
were found to be significantly regulated. Unfortunately, further functional studies of the 
latter genes proved limiting as differences in expression levels were small and these genes 
were not labeling distinct populations when labeled on TSNE plots. While CD34, CD36 
and PDGFRA were not among the pseudotime gradient of genes, they were certainly 
detected and thereby not missed in the preparation of SVF or subsequent treatments of the 
samples. While our results show a single adipose progenitor population in scWAT of 
healthy individuals, we cannot exclude a possibility of subtypes in subjects exhibiting 
obesity, insulin resistance or even within other adipose depots. Furthermore, an inherent 
weakness of our study is indeed the use of the Fluidigm C1 system as opposed to other 
methods, including single cell FACS sorting following my mRNA sequencing. The C1 
microfluidic chip used for this study was designed to capture cells within a specific 
diameter range, 10-17 µm, which excludes the smaller and larger cell not captured by 
chance. Thus, there is a possibility that some progenitor subtypes were missed although 
our measures did calculate a majority of progenitor cell diameters to fall within this 
range. Additionally, this study assessed heterogeneity from the mRNA level and found no 
evidence of subtypes. If heterogeneity is detectable by mRNA levels then it could 
possibly require sequencing of many more single cells than were feasible at the time the 
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study was performed. However, this cannot exclude the possibility that heterogeneity is 
not evident by mRNA analyses alone and must be complemented with other analyses, 
e.g. epigenetics or gene-specific approaches. Furthermore, it is critically important to 
keep in context that studies which show heterogeneity in adipose progenitor cells have 
been performed in murine models and those findings may owe to species differences [71, 
72]. This study has an inherent strength in that it performed single-cell RNA sequencing 
of more than 33,000 stromal cells from two murine adipose depots under in vivo control 
and treatment conditions [72]. This is more than a 50-fold difference relative to Study 
III. However, such a study is very difficult to perform in humans given patient specific 
differences compared to single genetic background that is most often used in murine 
studies.  
 Furthermore, an interesting finding was observed in relation to Studies I and II, 
multiple macrophage clusters. The literature has long been at odds with the widely-used 
M1-M2 macrophage nomenclature insisting that it was too simplistic a characterization of 
a complex cell type. Furthermore these assessments were based on in vitro polarization 
programs, which are not always reflective of the in vivo state. Our data show that there 
are at least 3 macrophage subtypes in scWAT of healthy subjects which we called M1-
like, M2-like and, interestingly, and intermediate phenotype, which could possibly have a 
role independent of inflammation. We should also mention that the expression of 
macrophage populations-specific genes defined by single-cell sequencing was 
investigated in FACS-sorted SVF fractions where M1 macrophages were defined as 
CD45+/CD14+/CD206+/CD11c+ cells and M2 as CD11c- cells. Therefore, it would be 
more correct to say that one cluster of cells mapped to CD11c+ and the other to CD11c- 
population and the third one mapped to both. The exact phenotypes and possible origins 
of the cells belonging to these clusters in addition to functional characterization remain to 
be determined in future investigations.  
 Finally, although the ability of our analysis to separate macrophage subtypes validates 
the approach in general, it failed to reveal heterogeneity of adipose progenitor cells 
meaning that these cells most likely exhibit very minor differences compared to 
macrophage cell populations. Though, our study was limited by study size, 
transcriptomes analyzed, and a lack of disease states for comparison it was the first of its 
kind in human adipose tissue. 
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Chapter 6             
Concluding Remarks and Future 
Perspectives 
This thesis aimed to study inflammation and adipogenesis capacity in human 
subcutaneous white adipose tissue with respect to the development of obesity and 
associated comorbidities, including insulin resistance. What we found was elevated 
expression of MAFB, a now important mediator of adipose tissue inflammation, with 
respect to BMI, increased adipocyte hypertrophy, and a shift in macrophage phenotypes 
in relation to insulin resistance. Furthermore, we found that in healthy subjects the age-
old question of what causes hypertrophic or hyperplastic adipose tissue cannot be easily 
addressed looking in search for distinct populations of progenitor cells, Figure 6.1. In 
addition, our data confer a result which the macrophage world has long considered, 
multiple macrophage subtypes; this is a concept which exceeds the bounds of the 
classical (M1) vs alternative (M2) activation polarization paradigm.  
 Interestingly, MAFB did not seem to mediate metabolic consequences on its own 
although it was certainly expressed throughout the adipogenesis program. It can be 
speculated that MAFB functions through CEBPD to affect adipocyte size indirectly. Now 
established as an interesting marker of adipose tissue inflammation, there is potential for 
MAFB to serve as a therapeutic target in adipocytes specifically as MAFB mRNA 
disturbances could lead to improved adipogenic capacity by way of a reduced TNFα-
signaling capacity.  
 Adipocyte hypertrophy was the focal point of Study II and the initiator or Study III. 
We found that adipocyte size corresponded adverse metabolic clinical phenotypes as well 
as inflammatory macrophage content. Addressing this issue would be of key clinical 
emphasis where one avenue could be through the improvement of the thiazolidinediones 
class of drugs which activate PPARγ and thereby improve adipogenic capacity. One such 
drug used to treat patients with type 2 diabetes is rosiglitazone which had been removed 
from the market due to elevated risk of myocardial infarction and death [148]. However, 
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recent meta-analyses confirm [149] or question [150] the significance of these findings. 
In either case, more investigation is needed into this class of anti-diabetic drugs. These 
three studies cemented a role for macrophages in the forefront of adipose research by 
confirming inflammatory and metabolic roles but also stoking the flames of a paradigm 
shift in macrophage classification. Study II utilized established adipose tissue 
macrophage markers whereby mixed phenotypes had been reported for cells expressing 
markers of classical or alternative activation [54, 77]. Study III supported this notion of 
multiple phenotypes, or even a possibility of varied macrophage origin [83-85], by 
reporting at least three ATM subtypes. 
 
 
Figure 6.1 Central findings in this thesis. Adipose progenitor cells consist of one 
homogeneous population. Dysregulated adipogenesis leads to hypertrophic adipose 
tissue during obesogenic conditions which is further characterized by increased rates of 
basal lipolysis. Macrophage populations become imbalanced leading to a pro-
inflammatory microenvironment. Image adapted, in part, from Chan et. al [147]. 
DOI: 10.1042/CS20180041 
Indeed, there is much more work to be done. It is imperative to this field of research to 
follow-up these studies and investigate differences between progenitors of healthy 
subjects with subjects displaying clinically relevant conditions, e.g. obesity, insulin 
resistance, dyslipidemia, and type 2 diabetes. Many more cells from larger cohorts would 
be needed for such an endeavor. It would take decades to acquire patient samples to 
answer critical questions to ascertain the impact of disease state, BMI status, weight loss 
effects on adipose biology, and inflammation on adipogenesis and adipose composition. 
Such a study would benefit from paired human adipose biopsies from both scWAT and 
visceral WAT. Further, it would require skilled bioinformatics analysts to separate 
technical noise from biologically relevant output, to combine sequencing, proteomics and 
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flow cytometric data from the same cohorts of individuals as well as state-of-art 
techniques of functional analysis. Such investigations are indeed ambitious endeavors; 
however, they provide opportunity for major advancement in the field of adipose biology. 
While the monetary investment would undoubtedly be high, the potential for curbing the 
progression of metabolic diseases is arguably worthwhile.  
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